Sanofi India Limited has informed the Exchange regarding a press release titled "SIL declares net sale YTD growth as -2% and Profit from Operations growth as +6% vs previous year".
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India reported a 9% decline in net sales on a comparable continuing business basis for the quarter ended June 30, 2025. Year-to-date, net sales fell 2% versus the previous year, but profit from operations grew 6% thanks to cost optimization and better operational efficiency. In the domestic market, the diabetes portfolio stayed strong, with Toujeo posting high single-digit growth and the newly launched premium insulin Soliqua gaining traction. Strategic partnerships in cardiovascular (CV) and central nervous system (CNS) segments are progressing as planned. Export sales were a drag, hit by the non-recurrence of one-time CHC (consumer healthcare) product sales from 2024 and the planned discontinuation of the Zentiva portfolio.
Mixed signals for shareholders — top-line is under pressure from export headwinds and portfolio pruning, but margin expansion through cost discipline is cushioning operating profit. The stock may see a neutral-to-slightly-negative reaction, with investors weighing the revenue decline against the steady profit growth.